10250-63-2

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 1-METHYL-3-PHENYL-1H-PYRAZOLE-5-CARBOXYLATE is used as a key intermediate in the synthesis of various pharmaceutical drugs for its analgesic, anti-inflammatory, anti-cancer, anti-bacterial, and anti-fungal properties.
Used in Analgesic Applications:
ETHYL 1-METHYL-3-PHENYL-1H-PYRAZOLE-5-CARBOXYLATE is used as an analgesic agent to relieve pain, contributing to the development of pain management medications.
Used in Anti-Inflammatory Applications:
ETHYL 1-METHYL-3-PHENYL-1H-PYRAZOLE-5-CARBOXYLATE is used as an anti-inflammatory agent to reduce inflammation and swelling, playing a role in the formulation of treatments for inflammatory conditions.
Used in Anti-Cancer Applications:
ETHYL 1-METHYL-3-PHENYL-1H-PYRAZOLE-5-CARBOXYLATE is used as an anti-cancer agent in the development of chemotherapeutic drugs, targeting cancer cells and inhibiting their growth.
Used in Anti-Bacterial Applications:
ETHYL 1-METHYL-3-PHENYL-1H-PYRAZOLE-5-CARBOXYLATE is used as an anti-bacterial agent in the creation of antibiotics, combating bacterial infections and promoting healing.
Used in Anti-Fungal Applications:
ETHYL 1-METHYL-3-PHENYL-1H-PYRAZOLE-5-CARBOXYLATE is used as an anti-fungal agent in the formulation of anti-fungal medications, treating fungal infections and preventing their spread.
Synthesis:
The synthesis of ETHYL 1-METHYL-3-PHENYL-1H-PYRAZOLE-5-CARBOXYLATE involves the reaction of phenylhydrazine with ethyl acetoacetate, followed by cyclization, methylation, and decarboxylation, resulting in the formation of this versatile chemical compound.

InChI:InChI=1/C13H14N2O2/c1-3-17-13(16)12-9-11(14-15(12)2)10-7-5-4-6-8-10/h4-9H,3H2,1-2H3

Upstream product

• 64-17-5 ethanol 
• 7339-53-9 methyl hydrazine hydrochloride 
• 10199-51-6 1-methyl-5-phenyl-1H-prazole-3-carboxylic acid ethyl ester 
• 98-86-2 acetophenone 
• 95-92-1 oxalic acid diethyl ester 
• 60-34-4 methylhydrazine 
• 6296-54-4 ethyl 2,4-dioxo-4-phenylbutyrate 
• 302-15-8 methylhydrazine sulfuric acid 
• 5932-30-9 ethyl 5-phenylpyrazole-3-carboxylate 
• 74-88-4 methyl iodide 
• 472800-84-3 ethyl (3Z)-4-hydroxy-2-oxo-4-phenylbut-3-enoate 

Downstream Products

• 10250-64-3 2-Methyl-5-phenyl-2H-pyrazole-3-carboxylic acid 

Relevant academic research and scientific papers

FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR

The present invention discloses a five-membered heterocyclic amide WNT pathway inhibitor, which belongs to a compound that regulates the activity of a Wnt signaling pathway, and provides a method for preparing such a compound, and the use of such a compound in preparing a medicament that antagonizes the Wnt signaling pathway. The five-membered heterocyclic amide WNT pathway inhibitor provided by the invention has a remarkable anti-tumor activity based on a target-based rational drug design of, and can be used for the development of a new generation of Wnt pathway inhibitors, and has a great clinical application value and considerable market potential.

C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION

This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.

SUBSTITUTED 1H-PYRAZOL-1,2,4-OXADIAZOLE DERIVATIVES AS SPHINGOSINE RECEPTOR MODULATORS

The present invention relates to substituted 1H-pyrazol-1,2,4-oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

ANTIBACTERIAL BENZOIC ACID DERIVATIVES

The invention provides antimicrobial agents and methods of using the agents for sterilization, sanitation, antisepsis, disinfection, and treatment of infections in mammals.

New pyrazolium-carboxylates as structural analogues of the pseudo-cross-conjugated betainic alkaloid nigellicine

Pyrazolium-3-carboxylates were examined as relatives of the betainic alkaloid Nigellicine and as new examples of the sparsely populated class 16 of heterocyclic pseudo-cross-conjugated mesomeric betaines (PCCMB). The title compounds were prepared in a 4-step procedure starting from β-diketo compounds 8 which were cyclized with substituted hydrazines. The resulting isomeric pyrazole esters 9 and 10 were separated and subsequently quaternized with dimethyl sulfate in the presence of nitrobenzene to pyrazolium esters 11 and 12. Saponification was best accomplished in diluted sulfuric acid, which resulted in the formation of the pseudo-cross-conjugated mesomeric betaines 13 and 14 in one step. Protonation to the corresponding carboxylic acids required the treatment of the betaines with tetrafluoroboric acid in dichloromethane. The effect of negative solvatochromism proves the charge separation in the ground state of the molecules. X-ray crystallographic analyses, semiempirical calculations, and ESI mass spectrometric measurements were performed to gain knowledge about the phenomenon of pseudo-cross-conjugation.

CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME

The present invention provides a novel carboxylic acid compound, a salt thereof or a hydrate of them useful as an insulin-resistant improver, and a medicament comprising the compound as an active ingredient. That is, the present invention provides a carboxylic acid compound represented by the following formula (I), a salt thereof, an ester thereof or a hydrate of them. In the formula, R1 represents hydrogen atom, hydroxyl group or a C1-6 alkyl group etc. which may have one or more substituents; L represents a single or double bond or a C1-6 alkylene group etc. which may have one or more substituents; M represents a single bond or a C1-6 alkylene group etc. which may have one or more substituents; T represents a single bond or a C1-3 alkylene group which may have one or more substituents; W represents carboxyl group or a group represented by the formula -CON(Rw1)Rw2 (wherein Rw1 and Rw2 are the same as or different from each other and each represents hydrogen atom, formyl group etc.) etc.; represents a single or double bond; X represents oxygen atom or a C2-6 alkenylene group etc. which may have one or more substituents; Y represents a C5-12 aromatic hydrocarbon group etc. which may have one or more substituents and which may have one or more heteroatoms; and ring Z represents a C5-6 aromatic hydrocarbon group which may have 0 to 4 substituents and which may have one or more heteroatoms.

N-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia

NHE-1 inhibitors, methods of using such NHE-1 inhibitors and pharmaceutical compositions containing such NHE-1 inhibitors. The NHE-1 inhibitors are useful for the reduction of tissue damage resulting from tissue ischemia.

Haloacetylated enol ethers. 11 [16]. Synthesis of 1-methyl- and 1- phenyl pyrazole-3(5)-ethyl esters. A one-pot procedure

A one-pot synthesis of 1-methyl- and 1-phenylpyrazole-3(5)-ethyl esters 2,3a-e by the cyclocondensation of β-alkoxyvinyl trichloromethyl ketones 1a- e with methyl and phenyl hydrazine hydrochloride under mild conditions, is reported. A study using compounds la-e with different substituents proved that these are versatile building blocks for the synthesis of pyrazole derivatives, having a 3(5)-ethoxycarbonyl substituent in good yields (60- 89%). The hydrazine and β-alkoxyvinyl trichloromethyl ketone substituent effects on the reaction regiochemistry on the formation of the 1,3- and 1,5- isomer were observed.